Accelere

Acellera is a drug discovery company that leverages artificial intelligence and quantum chemistry to accelerate the development of novel small-molecule therapeutics. The company's core technology, QuantumBind, combines the accuracy of quantum mechanics with the speed of machine learning to optimize lead molecules and identify high-affinity hits across a diverse range of targets. Acellera maintains a robust internal pipeline focused on high-value targets in oncology, immunology, and infectious diseases, while also providing its PlayMolecule AI platform to global pharmaceutical partners. By bridging the gap between computational speed and chemical accuracy, the company aims to significantly reduce the time and cost associated with early-stage drug engineering.